Non-CF bronchiectasis enters the therapy frontier
Late-stage programs targeting non-CF bronchiectasis are creating the first specific therapy category for this long-overlooked condition.
Non-CF bronchiectasis has been managed with airway clearance, antibiotics, and inhaled steroids for decades without specific disease-modifying therapy. Late-stage programs targeting neutrophil-driven inflammation are now in pivotal trials. The diagnostic infrastructure question is whether routine pulmonology recognises and characterises the condition well enough for therapy to find eligible patients.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.